BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 10, 2018
View Archived Issues
Patient enrollment ongoing in phase I trial of the GBM vaccine candidate VBI-1901
Read More
Novartis patents novel HBsAg secretion inhibitors
Read More
Baxter buys two hemostasis products from Mallinckrodt
Read More
The Medicines Co. closes sale of infectious disease business unit to Melinta Therapeutics
Read More
TG Therapeutics obtains rights to Jiangsu Hengrui's BTK inhibitor program
Read More
Machine learning framework allows 99% accurate ligand binding predictions
Read More
Lenvima plus Keytruda obtains FDA breakthrough therapy designation in RCC
Read More
Axsome Therapeutics announces results of IDMC interim analysis of COAST-1 and CREATE-1 trials
Read More
Novel polycomb protein EED inhibitors identified at Novartis
Read More
Roche discovers novel cannabinoid CB2 receptor ligands
Read More
Incysus submits second IND application to FDA
Read More
AVID-200 shows promise for the treatment of myelodysplastic syndrome-related anemia
Read More
Nerviano Medical Sciences patents new HsPEK inhibitors
Read More
Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease
Read More
Molecular Partners reports initial data from phase II study of MP-0250 in multiple myeloma
Read More
Adapsyn enters into research collaboration with Pfizer
Read More
GenSight cleared by MHRA to begin phase I/II study of GS-030 gene therapy for retinitis pigmentosa
Read More
Teijin returns somavaratan rights to Versartis
Read More
European Commission extends Orkambi marketing authorization to children aged 6-11 years
Read More
Akcea Therapeutics starts phase IIb study of AKCEA-APOCIII-LRx
Read More
Axovant corrects data from pilot phase II study of nelotanserin
Read More
Advanced Proteome Therapeutics and Heidelberg Pharma advance collaboration
Read More
JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia
Read More
Japanese submission seeks approval of blinatumomab for relapsed or refractory B-cell precursor ALL
Read More